http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
The Application of a Green TeaPolypheno to Regenerative Medicine
현승휴,Kazuaku matsumura,김종윤 한국생체재료학회 2006 생체재료학회지 Vol.10 No.3
EGCG, a green tea polyphenol, known as an anti-oxidative agent, when used to preserve non-frozen tissues such as cornea, pancreatic islets and blood vessels, remarkably improves their viability and quality. Thus EGCG can be a good tissue-preserving agent for such purposes as tissue transportation and transplantation. Besides the preservative action, EGCG also has anti-proliferative and immunosuppressive actions, and prevents neo-intimal hyperplasia in vein grafts and graft rejections in various tissues, respectively. Therefore, the use of EGCG for preserving the living tissues and controlling these cellular responses will provide us a starting point to advance the future of regenerative medicine.
약물-용출 생분해성 고분자 스텐트를 위한 EGCG와 디자인 파라미터의 영향에 대한 연구
정태곤,이종호,이준재,현승휴,한동욱,Jung, T.G.,Lee, J.H.,Lee, J.J.,Hyon, S.H.,Han, D.W. 대한의용생체공학회 2013 의공학회지 Vol.34 No.3
Finite element analysis(FEA) has been extensively applied in the analyses of biomechanical properties of stents. Geometrically, a closed-cell stent is an assembly of a number of repeated unit cells and exhibits periodicity in both longitudinal and circumferential directions. This study concentrates on various parameters of the FEA models for the analysis of drug-eluting biodegradable polymeric stents for application to the treatment of coronary artery disease. In order to determine the mechanical characteristics of biodegradable polymeric stents, FEA was used to model two different types of stents: tubular stents(TS) and helicoidal stents(HS). For this modeling, epigallocatechin-3-O-gallate (EGCG)-eluting poly[(L-lactide-co-${\varepsilon}$-caprolactone), PLCL] (E-PLCL) was chosen as drug-eluting stent materials. E-PLCL was prepared by blending PLCL with 5% EGCG as previously described. In addition, the effects of EGCG blending on the mechanical properties of PLCL were investigated for both types of stent models. EGCG did not affect tensile strength at break, but significantly increased elastic modulus of PLCL. It is suggested that FEA is a cost-effective method to improve the design of drug-eluting biodegradable polymeric stents.
알데히드화 덱스트란과 폴리라이신으로 구성된 의료용 접착제의 창상 봉합 및 지혈 효능의 평가
이종호,정태곤,황대연,강현구,한동욱,현승휴 한국생체재료학회 2011 생체재료학회지 Vol.15 No.3
This study concentrates upon evaluating the wound closure and antihemorrhagic efficiency of a new biodegradable medical adhesive, Lydex, composed of aldehyded dextran and ε-poly(L-lysine). Each component of Lydex was mixed together and then immediately gelatinized to form an adhesive. Gel formation time of Lydex was approximately 20~30 sec at 25℃. The mechanism of Lydex gelation is based on Schiff base formation between aldehyded dextran and ε-poly(L-lysine). Lydex showed more excellent bonding strength and compressive stress than fibrin glue. The animal study in rat skin wounds (about 20 mm long) revealed that the wound closure efficiency of Lydex was superior to that of taping as (–) control after 10 d, but relatively inferior to that of Dermabond® as (+) control. The hemostatic effects of Lydex were evaluated on the rabbit liver with a surgical incision (critical-sized injury, about 20 mm long and about 5 mm deep). The hemorrhage quantity of Lydex-applied liver was significantly smaller than those of non-applied and fibrin glue-applied livers, showing that hemostasis was almost completed within 30 sec. Furthermore, when applied to surgically incised rabbit liver, Lydex bonded securely to the rabbit liver surface and tissue reaction of liver bonded to Lydex was mild without inflammation and abnormalities after 4 wk. The gel was decomposed with the progress in the time, and the complete degradation was done at 6 wk. These results suggest that a bioocompatible adhesive, Lydex could be effectively used as a medical adhesive with bleeding-stoppage function.
이종호,김현용,정태곤,한인호,박종철,박기동,최재봉,현승휴,한동근,한동욱 한국생체재료학회 2010 생체재료학회지 Vol.14 No.2
In the case of surgical operation for the treatment of cancers, vascular diseases and diabetes mellitus, the use of medical (or biotissue) adhesives is gradually increasing instead of suturing. Together with this trend, the development of anti-adhesion membranes (or barriers) is rapidly increasing for preventing complications originated from post-operative tissue adhesions frequently occurring. In general, all medical devices should pass the testing for biological safety and effectiveness. Thus, newly developed medical adhesives and anti-adhesion membranes must be evaluated according to the well-regulated standard guidelines, such as ISO, OECD, ASTM, etc, under authorized institution, otherwise they cannot be commercialized. In this review, medical adhesives and anti-adhesion membranes were categorized and compared according to their use and materials followed by a brief description of the properties of products commercially available. Furthermore, this review dealt with the present state of commercialization, the size of market and the recent trends of research and development regarding medical adhesives and anti-adhesion membranes